The US Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) target action date for Aldeyra’s New Drug Application (NDA) for reproxalap for the treatment of dry ...
Panelists discuss how the 8-mg aflibercept formulation improves drying efficacy, extends dosing intervals, and reduces burden ...
Panelists discuss how higher-dose and dual-pathway anti-VEGF agents enable longer intervals, improved fluid control, and more ...
Argenx SE has discontinued the phase 3 UplighTED studies evaluating efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in adults with moderate to severe thyroid eye disease (TED ...
Aviceda Therapeutics has released topline results from its phase 2b study, SIGLEC, evaluating AVD-104 in patients with ...
Recently reported findings indicate that cenegermin-bkbj ophthalmic solution (Oxervate; Dompé) may perform as an effective ...
Effective mentorship is crucial for combating burnout and enhancing teaching efficacy, with strategies like precharting, time blocking, and the Eisenhower Decision Matrix (EDM).
Azura Ophthalmics announced it has received positive feedback from a pre-New Drug Application (NDA) meeting with the US Food ...
New grading scales for ocular adverse events in oncology improve clarity and provide drug-dose-modification recommendations, ...
The authors wrote that early diagnosis, adherence to prolonged management, and constant monitoring can allow the cornea to ...
"Lubricating drops" is proposed as a more accurate term, reflecting their primary function of providing lubrication and ...
In the second part, the discussion turns to emerging DED therapies that target tear function and ocular surface homeostasis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback